Literature DB >> 10981158

Is there a preferred antihypertensive therapy for isolated systolic hypertension and reduced arterial compliance?

S S Franklin1.   

Abstract

Isolated systolic hypertension (ISH) is the most common type of hypertension and the most difficult type to control with antihypertensive therapy. ISH, by definition, is wide pulse pressure hypertension resulting largely from excessive large artery stiffness and representing an independent risk factor for cardiovascular disease in the older aged population. Two major intervention studies of ISH have shown significant benefit in reducing systolic blood pressure with active drug therapy, including thiazide diuretics and calcium receptor antagonists. The optimal treatment strategy is to maximize reduction in systolic blood pressure and to minimize reduction in diastolic blood pressure, thereby reducing pulse pressure. All classes of antihypertensive drugs reduce pulse pressure by means of lowering peripheral resistance, but certain drugs like nitrates, angiotensin converting enzyme inhibitors, and other drugs affecting the renin-angiotensin system have multiple actions that improve large artery stiffness and early wave reflection and are especially useful in treating ISH in the elderly.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10981158     DOI: 10.1007/s11906-000-0008-0

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  68 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

3.  Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a beta-blocker.

Authors:  E L Schiffrin; L Y Deng; P Larochelle
Journal:  Am J Hypertens       Date:  1995-03       Impact factor: 2.689

4.  Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study.

Authors:  S S Franklin; S A Khan; N D Wong; M G Larson; D Levy
Journal:  Circulation       Date:  1999-07-27       Impact factor: 29.690

5.  Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement.

Authors:  G F Mitchell; L A Moyé; E Braunwald; J L Rouleau; V Bernstein; E M Geltman; G C Flaker; M A Pfeffer
Journal:  Circulation       Date:  1997-12-16       Impact factor: 29.690

6.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

7.  Early predictors of 15-year end-stage renal disease in hypertensive patients.

Authors:  H M Perry; J P Miller; J R Fornoff; J D Baty; M P Sambhi; G Rutan; D W Moskowitz; S E Carmody
Journal:  Hypertension       Date:  1995-04       Impact factor: 10.190

8.  Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review.

Authors:  F H Messerli; E Grossman; U Goldbourt
Journal:  JAMA       Date:  1998-06-17       Impact factor: 56.272

9.  The natural history of borderline isolated systolic hypertension.

Authors:  A Sagie; M G Larson; D Levy
Journal:  N Engl J Med       Date:  1993-12-23       Impact factor: 91.245

10.  Blood pressure screening, management and control in England: results from the health survey for England 1994.

Authors:  H M Colhoun; W Dong; N R Poulter
Journal:  J Hypertens       Date:  1998-06       Impact factor: 4.844

View more
  7 in total

Review 1.  The effect of antihypertensive drugs on vascular compliance.

Authors:  N Winer; M A Weber; J R Sowers
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

2.  Isolated Systolic Hypertension in the Elderly.

Authors:  Claudia U. Chae; Donald M. Lloyd-Jones
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-02

Review 3.  Prevalence and implications of uncontrolled systolic hypertension.

Authors:  William B Kannel
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

4.  The effect of a losartan-based treatment regimen on isolated systolic hypertension.

Authors:  William C Cushman; William E Brady; Lisa P Gazdick; Robert K Zeldin
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Mar-Apr       Impact factor: 3.738

5.  Effectiveness of olmesartan-based treatment on home and clinic blood pressure in elderly patients with masked and white coat hypertension.

Authors:  Toshio Kushiro; Kazuomi Kario; Ikuo Saito; Satoshi Teramukai; Yoshihiro Mori; Yasuyuki Okuda; Kazuyuki Shimada
Journal:  Hypertens Res       Date:  2014-10-30       Impact factor: 3.872

Review 6.  The evolution of systolic blood pressure as a strong predictor of cardiovascular risk and the effectiveness of fixed-dose ARB/CCB combinations in lowering levels of this preferential target.

Authors:  Jean-Jacques Mourad
Journal:  Vasc Health Risk Manag       Date:  2008

Review 7.  Hypertension and the elderly: more than just blood pressure control.

Authors:  Lawrence Baruch
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-05       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.